Skip to content

Clinical trials

Ovarian Neoplasms trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Ovarian Neoplasms Country / region: United Kingdom Clear all

280 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
20013
20023
20032
20043
20058
200611
20078
20089
200910
20109
201110
20127
201315
201414
20158
201613
201712
201811
20199
202012
202122
202212
202310
202417
202511
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed137
Recruiting48
Terminated33
Unknown status30
Active, not recruiting28
Withdrawn3
Not yet recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AstraZeneca23
Cancer Research UK10
Royal Marsden NHS Foundation Trust10
European Organisation for Research and Treatment of Cancer - EORTC8
Incyte Corporation7
Medical Research Council7
University College, London7
Astellas Pharma Inc6
Hoffmann-La Roche6
Imperial College London6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Ovarian Neoplasms280
Fallopian Tube Neoplasms67
Carcinoma, Ovarian Epithelial51
Carcinoma, Non-Small-Cell Lung43
Endometrial Neoplasms43
Breast Neoplasms37
Colorectal Neoplasms33
Neoplasms32
Uterine Cervical Neoplasms32
Urinary Bladder Neoplasms26

Trials

Showing 1 to 25 of 280. Each trial links to its page on Pharma Observatory.

180 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.